Literature DB >> 11114264

Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease--a stereological approach.

C Banerjee1, J R Nyengaard, A Wevers, R A de Vos, E N Jansen Steur, J Lindstrom, K Pilz, S Nowacki, W Bloch, H Schröder.   

Abstract

Cognitive deficits in Alzheimer's and Parkinson's disease are closely related to disturbed cholinergic transmission. The decrease of nicotinic acetylcholine receptor protein has been assessed by Western blotting and immunohistochemistry. Stereology, however, has not been used to assess numbers of receptor-expressing human cerebrocortical neurons. Our approach applies a combination of alpha7 subunit-immunohistochemistry with a stereological technique using defined stretches of pial surface as reference standard. The number of alpha7 subunit protein-expressing neurons in the Alzheimer temporal cortices amounted to approximately half of that of controls while numbers in Parkinson patients lay in between. No differences in the total number of neurons were seen. These results corroborate nonstereological studies on Alzheimer cortices and for the first time show a similar decrease in receptor expression in Parkinson's disease. They provide evidence that not only Alzheimer dementia but also cognitive deficits in Parkinson's disease may be related to decreased nicotinic receptor expression. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114264     DOI: 10.1006/nbdi.2000.0317

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  29 in total

1.  Some properties of human neuronal alpha 7 nicotinic acetylcholine receptors fused to the green fluorescent protein.

Authors:  Eleonora Palma; Anna M Mileo; Ataulfo Martinez-Torres; Fabrizio Eusebi; Ricardo Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

2.  Utilizing pHluorin-tagged Receptors to Monitor Subcellular Localization and Trafficking.

Authors:  Ashley M Fox-Loe; Brandon J Henderson; Christopher I Richards
Journal:  J Vis Exp       Date:  2017-03-16       Impact factor: 1.355

3.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

Review 4.  α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimum.

Authors:  Victor V Uteshev
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 5.  Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms.

Authors:  G Mudo; N Belluardo; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2006-08-17       Impact factor: 3.575

6.  Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease.

Authors:  Salvatore Oddo; Antonella Caccamo; Kim N Green; Kevin Liang; Levina Tran; Yiling Chen; Frances M Leslie; Frank M LaFerla
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-10       Impact factor: 11.205

7.  Assembly of alpha4beta2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons.

Authors:  Raad Nashmi; Mary E Dickinson; Sheri McKinney; Mark Jareb; Cesar Labarca; Scott E Fraser; Henry A Lester
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

Review 8.  Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.

Authors:  Ana Sofía Vallés; María Virginia Borroni; Francisco J Barrantes
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

9.  Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.

Authors:  Richard T Reid; Marwan N Sabbagh
Journal:  J Neural Transm (Vienna)       Date:  2008-08-26       Impact factor: 3.575

Review 10.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.

Authors:  Evelin L Schaeffer; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.